secwatch.observer — SEC 8-K summary
======================================

Issuer:     BUTLER NATIONAL CORP (BUKS)
CIK:        0000015847
Form:       8-K
Filed at:   2026-06-01T16:41:32+00:00
Accession:  0000015847-26-000009
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Christopher Reedy discloses ongoing cancer treatment; remains in role
-------------------------------------------------------------------------

- CEO Christopher Reedy informed employees of new medical treatment following Mayo Clinic consultations; he has continued follow-ups since 2019 cancer diagnosis.
- Reedy will continue as CEO and remain actively engaged with operations, leadership team, and Board.
- Executive Chairman Jeffrey D. Yowell and Lead Independent Director Joseph P. Daly expressed full Board support for Reedy.
- Treatment may periodically require time away from office; executive leadership team and Board will support ongoing operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/0000015847-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/15847/000001584726000009/buks-20260601.htm
  HTML page:      https://secwatch.observer/filing/0000015847-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer